Madlen Jentzsch Selected Research

Neoplasms (Cancer)

3/2021	Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation.
1/2021	Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome.
1/2020	Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible.
12/2019	Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Madlen Jentzsch Research Topics

Disease

18	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2022 - 01/2016
4	Multiple Myeloma 08/2021 - 11/2015
4	Neoplasms (Cancer) 03/2021 - 12/2019
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2021 - 01/2019
3	Leukemia 10/2020 - 04/2017
3	Pathologic Complete Response 01/2020 - 04/2017
2	Lymphoma (Lymphomas) 01/2021 - 01/2021
2	Residual Neoplasm 01/2020 - 04/2017
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2022
1	Weight Loss (Weight Reduction) 03/2021
1	Large Granular Lymphocytic Leukemia 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Sezary Syndrome (Sezary Erythroderma) 01/2021
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 05/2020
1	Septic Shock (Toxic Shock Syndrome) 05/2020
1	Bacterial Meningitis 05/2020
1	Sepsis (Septicemia) 05/2020
1	Mast-Cell Leukemia (Leukemia, Mast Cell) 01/2020
1	Mast-Cell Sarcoma 01/2020
1	Wilms Tumor (Wilm's Tumor) 02/2019
1	Thrombotic Thrombocytopenic Purpura 05/2015
1	acquired Thrombotic thrombocytopenic purpura 05/2015
1	Pancreatitis 05/2015

Drug/Important Bio-Agent (IBA)

5	Bendamustine Hydrochloride FDA Link 08/2021 - 11/2015
3	Bortezomib (Velcade)FDA Link 08/2021 - 11/2015
3	Prednisone (Sone)FDA LinkGeneric 08/2021 - 11/2015
2	Biological ProductsIBA 11/2021 - 04/2017
2	Rituximab (Mabthera)FDA Link 01/2021 - 05/2015
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 04/2022
1	Chimeric Antigen ReceptorsIBA 01/2021
1	polatuzumab vedotinIBA 01/2021
1	Brentuximab VedotinIBA 01/2021
1	eculizumab FDA Link 05/2020
1	Complement Inactivating AgentsIBA 05/2020
1	CPX-351IBA 01/2020
1	NucleophosminIBA 02/2019
1	Lenalidomide (CC 5013)FDA Link 12/2017
1	Prednisolone (Predate)FDA LinkGeneric 12/2017
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2016
1	fludarabineIBA 01/2016
1	Amsacrine (AMSA)IBA 01/2016
1	AutoantibodiesIBA 05/2015
1	thiamine triphosphorate (TTP)IBA 05/2015
1	Metalloproteases (Metalloproteinases)IBA 05/2015

Therapy/Procedure

11	Stem Cell Transplantation 10/2022 - 11/2015
11	Hematopoietic Stem Cell Transplantation 01/2022 - 01/2016
10	Therapeutics 11/2021 - 04/2017
5	Drug Therapy (Chemotherapy) 03/2021 - 04/2017
4	Homologous Transplantation 01/2020 - 04/2017
2	Hematopoietic Stem Cell Mobilization 01/2022 - 11/2015
1	Salvage Therapy 01/2021
1	Transplantation 01/2021
1	Radiotherapy 01/2020